Literature DB >> 18419396

Varicella vaccination in Australia and New Zealand.

Kristine K Macartney1, Margaret A Burgess.   

Abstract

Varicella-zoster virus has been responsible for a significant disease burden, including hospitalizations and deaths in Australia and New Zealand. Varicella vaccine has been available in Australia since 1999 and, since November 2005, has been funded under the National Immunisation Program for use in all children as a single dose at 18 months of age and in a school-based catch-up program at 10-13 years of age. Recent hospitalization data from Australia show a decline in varicella hospitalizations in children 1-4 years of age, most likely related to vaccination. In New Zealand, varicella vaccine has been available since 1999 but is currently not recommended or funded on the New Zealand national immunization schedule. The anticipated licensure of combination measles-mumps-rubella-varicella vaccines in both countries may lead to future schedule changes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419396     DOI: 10.1086/522157

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Economic evaluation of Varicella vaccination: results of a systematic review.

Authors:  Brigid Unim; Rosella Saulle; Sara Boccalini; Cristina Taddei; Vega Ceccherini; Antonio Boccia; Paolo Bonanni; Giuseppe La Torre
Journal:  Hum Vaccin Immunother       Date:  2013-07-03       Impact factor: 3.452

2.  Varicella vaccine uptake in Shandong Province, China.

Authors:  Aiqiang Xu; Qing Xu; Xueqiang Fang; Stephanie Bialek; Chengbin Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

3.  Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.

Authors:  Kristine Macartney; Heather F Gidding; Lieu Trinh; Han Wang; Aditi Dey; Brynley Hull; Karen Orr; Jocelynne McRae; Peter Richmond; Michael Gold; Nigel Crawford; Jennifer A Kynaston; Peter McIntyre; Nicholas Wood
Journal:  JAMA Pediatr       Date:  2017-10-01       Impact factor: 16.193

4.  Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.

Authors:  Ui Yoon Choi; Dong Ho Huh; Jong Hyun Kim; Jin Han Kang
Journal:  Hum Vaccin Immunother       Date:  2016-08-02       Impact factor: 3.452

5.  Literature Review on One-Dose and Two-Dose Varicella Vaccination: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors:  Alexia Campbell; Shainoor Ismail; Ben Tan
Journal:  Can Commun Dis Rep       Date:  2010-10-18

6.  Health technology assessment of varicella vaccine in the Armed Forces.

Authors:  Seema Patrikar; V K Bhatti; Vani Suryam; A Kotwal; D R Basannar; A Khera; Surekha Kashyap; Ashutosh Sharma
Journal:  Med J Armed Forces India       Date:  2021-08-13

7.  Varicella vaccine uptake and associated factors in children in Hong Kong.

Authors:  J Y C Chan; K M Leung; W W S Tam; A Lee
Journal:  Epidemiol Infect       Date:  2013-08-12       Impact factor: 4.434

Review 8.  Varicella vaccination in Europe - taking the practical approach.

Authors:  Paolo Bonanni; Judith Breuer; Anne Gershon; Michael Gershon; Waleria Hryniewicz; Vana Papaevangelou; Bernard Rentier; Hans Rümke; Catherine Sadzot-Delvaux; Jacques Senterre; Catherine Weil-Olivier; Peter Wutzler
Journal:  BMC Med       Date:  2009-05-28       Impact factor: 8.775

9.  Evaluation of a vaccination strategy by serosurveillance data: The case of varicella.

Authors:  Silvio Tafuri; Maria Serena Gallone; Maria Filomena Gallone; Maria Giovanna Cappelli; Maria Chironna; Cinzia Germinario
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial.

Authors:  Roman Prymula; Robert Simko; Michael Povey; Andrea Kulcsar
Journal:  BMC Pediatr       Date:  2016-01-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.